JP2002544137A - C17アルキル側鎖および芳香族a環をもつ治療に使用するステロイド化合物 - Google Patents

C17アルキル側鎖および芳香族a環をもつ治療に使用するステロイド化合物

Info

Publication number
JP2002544137A
JP2002544137A JP2000616220A JP2000616220A JP2002544137A JP 2002544137 A JP2002544137 A JP 2002544137A JP 2000616220 A JP2000616220 A JP 2000616220A JP 2000616220 A JP2000616220 A JP 2000616220A JP 2002544137 A JP2002544137 A JP 2002544137A
Authority
JP
Japan
Prior art keywords
group
cholesta
formula
hydroxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000616220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002544137A5 (cg-RX-API-DMAC7.html
Inventor
ロバート・ヘンリー・ヘス
スンダーラ・カテュガム・スリーニヴァーサセティ・セティ
マーラーティ・ラームゴパール
サンガ・クーガバルソーリアー
Original Assignee
リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド filed Critical リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド
Publication of JP2002544137A publication Critical patent/JP2002544137A/ja
Publication of JP2002544137A5 publication Critical patent/JP2002544137A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
JP2000616220A 1999-05-11 2000-05-11 C17アルキル側鎖および芳香族a環をもつ治療に使用するステロイド化合物 Pending JP2002544137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9910934.0 1999-05-11
GBGB9910934.0A GB9910934D0 (en) 1999-05-11 1999-05-11 Chemical compounds
PCT/GB2000/001813 WO2000068246A1 (en) 1999-05-11 2000-05-11 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy

Publications (2)

Publication Number Publication Date
JP2002544137A true JP2002544137A (ja) 2002-12-24
JP2002544137A5 JP2002544137A5 (cg-RX-API-DMAC7.html) 2007-06-21

Family

ID=10853250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000616220A Pending JP2002544137A (ja) 1999-05-11 2000-05-11 C17アルキル側鎖および芳香族a環をもつ治療に使用するステロイド化合物

Country Status (21)

Country Link
US (2) US6881730B1 (cg-RX-API-DMAC7.html)
EP (1) EP1179005B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002544137A (cg-RX-API-DMAC7.html)
KR (1) KR100690040B1 (cg-RX-API-DMAC7.html)
CN (1) CN1158297C (cg-RX-API-DMAC7.html)
AT (1) ATE254629T1 (cg-RX-API-DMAC7.html)
AU (1) AU779743B2 (cg-RX-API-DMAC7.html)
CA (1) CA2373443A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ297316B6 (cg-RX-API-DMAC7.html)
DE (1) DE60006665T2 (cg-RX-API-DMAC7.html)
DK (1) DK1179005T3 (cg-RX-API-DMAC7.html)
ES (1) ES2207509T3 (cg-RX-API-DMAC7.html)
GB (1) GB9910934D0 (cg-RX-API-DMAC7.html)
HK (1) HK1046001B (cg-RX-API-DMAC7.html)
HU (1) HUP0201047A3 (cg-RX-API-DMAC7.html)
IL (2) IL146442A0 (cg-RX-API-DMAC7.html)
NO (1) NO319949B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ515482A (cg-RX-API-DMAC7.html)
PT (1) PT1179005E (cg-RX-API-DMAC7.html)
WO (1) WO2000068246A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200109272B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532737A (ja) * 2000-05-11 2003-11-05 リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド 2位置換プレグナ−1,3,5(10)−トリエン誘導体およびコラン−1,3,5(10)−トリエン誘導体およびそれらの生物活性
JP2014526469A (ja) * 2011-09-08 2014-10-06 セージ セラピューティクス, インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
GB9910934D0 (en) * 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
EP1343803A2 (en) * 2000-11-27 2003-09-17 EntreMed, Inc. 2-substituted estrogens as antiangiogenic agents
WO2002092100A1 (en) * 2001-05-11 2002-11-21 Marsden, John, Christopher 17-(c(ch3) (ch2) o-3c (r4, r5) n (r6, r7))-substituted 19-nor-pregna-1, 3, 5(10)-triene derivatives and their medical use
WO2005030120A2 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
AU2005222934B2 (en) 2004-03-12 2010-06-17 Entremed, Inc. Antiangiogenic agents
US8399440B2 (en) 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
DK2407475T3 (en) * 2007-06-19 2015-10-26 Kythera Biopharmaceuticals Inc Preparation of synthetic bile acid
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
FI3932932T3 (fi) 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス, インコーポレイテッド オキシステロールおよびその使用方法
PT3319611T (pt) 2015-07-06 2021-04-22 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
DK3812392T3 (da) 2015-07-06 2025-07-21 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
DK3529257T3 (da) 2016-10-18 2023-08-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
CN115040524A (zh) * 2022-07-27 2022-09-13 深圳市中西医结合医院 4-胆甾烯-3-酮用于治疗多发性骨髓瘤骨病的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01229000A (ja) * 1988-03-09 1989-09-12 Snow Brand Milk Prod Co Ltd 2(3―ハイドロキシ―1,3,5(10)―エストリエン―17―イル)プロピオン酸の製造法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
GB1267915A (en) * 1968-05-24 1972-03-22 Glaxo Lab Ltd Ring a-substituted ring a-aromatic steroids
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
GB9910934D0 (en) * 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
US6967195B2 (en) * 2000-05-11 2005-11-22 Research Institute For Medicine And Chemistry, Inc. 2-substituted pregna-1-3,5(10) triene and chola-1,3,5(10) triene derivatives and their biological activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01229000A (ja) * 1988-03-09 1989-09-12 Snow Brand Milk Prod Co Ltd 2(3―ハイドロキシ―1,3,5(10)―エストリエン―17―イル)プロピオン酸の製造法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010050710, DOLENCE, E. K., "A stereoselective synthesis of 1,2−diols from α−hydroxyaldehydes", Tetrahedron Letters, 1985, 26(9), p. 1189−1192 *
JPN6010050711, LAJEUNESSE, D., "Effect of 17β−estradiol on the human osteosarcoma cell line MG−63", Bone and Mineral, 1994, 24(1), p. 1−16 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532737A (ja) * 2000-05-11 2003-11-05 リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド 2位置換プレグナ−1,3,5(10)−トリエン誘導体およびコラン−1,3,5(10)−トリエン誘導体およびそれらの生物活性
JP2014526469A (ja) * 2011-09-08 2014-10-06 セージ セラピューティクス, インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用

Also Published As

Publication number Publication date
CZ297316B6 (cs) 2006-11-15
WO2000068246A1 (en) 2000-11-16
IL146442A0 (en) 2002-07-25
NO20015520L (no) 2002-01-09
DE60006665T2 (de) 2004-10-07
ES2207509T3 (es) 2004-06-01
GB9910934D0 (en) 1999-07-14
HUP0201047A3 (en) 2003-07-28
HK1046001A1 (en) 2002-12-20
CA2373443A1 (en) 2000-11-16
NZ515482A (en) 2004-05-28
AU4596000A (en) 2000-11-21
NO319949B1 (no) 2005-10-03
ATE254629T1 (de) 2003-12-15
US20050171075A1 (en) 2005-08-04
KR100690040B1 (ko) 2007-03-09
IL146442A (en) 2006-10-05
EP1179005A1 (en) 2002-02-13
CZ20014049A3 (cs) 2002-04-17
EP1179005B1 (en) 2003-11-19
HK1046001B (en) 2004-12-24
US6881730B1 (en) 2005-04-19
AU779743B2 (en) 2005-02-10
PT1179005E (pt) 2004-04-30
ZA200109272B (en) 2003-02-26
HUP0201047A2 (en) 2002-08-28
CN1358193A (zh) 2002-07-10
KR20020013542A (ko) 2002-02-20
DK1179005T3 (da) 2004-03-01
CN1158297C (zh) 2004-07-21
DE60006665D1 (de) 2003-12-24
NO20015520D0 (no) 2001-11-12

Similar Documents

Publication Publication Date Title
US6881730B1 (en) Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
KR100690037B1 (ko) 콜렌산 아미드 및 이를 함유하는 약학적 조성물
EP0751932B1 (en) Vitamin-d amide derivatives
US6372926B2 (en) 17-side chain alkynyl-and 20-oxopregna-derivatives of vitamin D, methods for their production and pharmaceutical compositions thereof
CN100338088C (zh) 2-取代的孕-1,3,5(10)-三烯和胆-1,3,5(10)-三烯衍生物及其生物活性
US6967195B2 (en) 2-substituted pregna-1-3,5(10) triene and chola-1,3,5(10) triene derivatives and their biological activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110301